Pipeline

We have established licensing-in agreements for protein therapeutics and are pursuing indication expansion strategies across diverse therapeutic areas.

Our strategically licensed protein therapeutics portfolio. Both GF-103 and GF-203 are next-generation protein drugs acquired through strategic partnerships. Lead asset GF-103 has advanced to preclinical phase in Wet-AMD with promising results across multiple indications including mucositis, DME, and IBD. Follow-on asset GF-203 is in early development across similar indications. This phased approach enables effective risk management while building a robust protein therapeutics pipeline through strategic licensing.